Opioid switching is increasingly practiced. This patient did not tolerate morphine, oxycodone or hydromorphone due to opioid toxicity. Finally switch to alfentanil was performed. The patient developed classical opioid withdrawal symptoms and signs from discontinuation of the hydromorphone. Administration of small aliqouts of this drug reversed the symptoms. The existance of incomplete cross tolerance between hydromorphone and alfentanil is demonstrated.
1 WHO . The Analgesic Ladder, second edition. Geneva : World Health Organisation , 1996: 1–69.
2.
2 Cherny NRipamonti CPereira J . Strategies to manage the adverse effects of oral morphine: an evidence-based report.J Clin Oncol2001; 19: 2542 – 2554 .
3.
3 Quigley C; . Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews, 2004, issue 3.
4.
4 Urch CECarr SMinton O . A retrospective review of the use of alfentanil in a hospital palliative care setting.Palliat Med2004; 18: 516 – 519 .
5.
5 Davies ANBond C . Transdermal fentanyl and the opioid withdrawal syndrome.Palliat Med1996; 10: 348 .
6.
6 Zenz MDonner BStrumpf M . Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS).J Pain Symptom Manage1994; 9: 54 – 55 .
7.
7 Pasternak GW . Multiple opiate receptors: déjà vu all over again.Neuropharmacology2004; 47: 312 – 323 .
8.
8 Ross JRRutter DWelsh K . Clinical response to morphine in cancer patients and genetic variation in candidate genes.Pharmacogenom J2005; 5: 324 – 336 .
9.
9 Pasternak GW . Incomplete cross tolerance and multiple mu opioid peptide receptors.Trends Pharmacol Sci2001; 22: 67 – 70 .
